| High | $17.00 |
|---|---|
| Median | $11.63 |
| Low | $6.25 |
| Average | $11.63 |
| Current Price | $2.57 |
Is ispecimen (ISPC) stock headed to $20?
Today, Craig-Hallum initiated coverage of iSpecimen (NASDAQ:ISPC) with a “buy” rating and a price target of $20. This price target represents impressive upside of more than 120% from current prices. As a result, mention of ISPC stock on the popular financial site Stocktwits has increased by more than 21%.
How much is an ISPC stock worth?
One share of ISPC stock can currently be purchased for approximately $11.42. How much money does iSpecimen make? iSpecimen has a market capitalization of $79.91 million and generates $8.18 million in revenue each year.
What does ISPC stand for?
iSpecimen Inc. (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an online marketplace for human biospecimens, today announced it has recently expanded its global biospecimen provider network in support of research related to neurological disorders, which afflict around one billion people worldwide, or an estimated 1 in 6 people (UN).
Is ispecimen stock a buy at a discount?
ISPC stock currently trades at a multiple of 2.5x for 2022. Hewitt therefore believes iSpecimen trades at a discount relative to other platform-based and pharmaceutical businesses.
Quite a few insiders invested in iSpecimen Inc. (NASDAQ:ISPC) last year which is positive news for shareholders
iSpecimen Reports Full Year 2021 Financial Results
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
iSpecimen to Participate in the Aegis Virtual Conference on February 24, 2022
Record FY 2021 Revenue of $11.1 Million, Surpassing FY 2020 Revenue of $8.2 Million by 36%LEXINGTON, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online marketplace for human biospecimens, today reported its financial results for the three and twelve-month periods ended December 31, 2021.
52 Biggest Movers From Friday
LEXINGTON, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ: ISPC) (“iSpecimen” or the “Company”), an online marketplace for human biospecimens, today announced that Christopher Ianelli, MD, PhD, CEO and President, will participate in the Aegis Capital Corp. Virtual Conference to be held virtually on February 23-25, 2022. Dr.
30 Stocks Moving In Friday's Mid-Day Session
Gainers Splash Beverage Group, Inc. (NASDAQ: SBEV) shares gained 118.9% to settle at $4.18 on Friday. Splash Beverage recently announced it has received authorization to sell its TapouT performance drink in Walmart stores across Florida metropolitan areas.
Signals & Forecast
Gainers ATI Physical Therapy, Inc. (NYSE: ATIP) shares gained 25.2% to $3.8050 after Jefferies upgraded the stock from Hold to Buy and raised its price target from $3.50 to $5.
Support, Risk & Stop-loss
There are mixed signals in the stock today. The iSpecimen Inc. stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average.
Is iSpecimen Inc. stock A Buy?
iSpecimen Inc. finds support from accumulated volume at $3.92 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Insiders are very positive buying more shares than they are selling in iSpecimen Inc
iSpecimen Inc. holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock. We have upgraded our analysis conclusion for this stock since the last evaluation from a Strong Sell to a Sell candidate.
Golden Star Signal
In the last 59 trades there were 2.2 million shares bought and 595.51 thousand shares sold. The last trade was done 2 days ago by Mullan Jill who sold 3.1 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Historical and forecast chart of iSpecimen stock
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
iSpecimen Daily Price Targets
The chart below shows the historical price of iSpecimen stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the iSpecimen stock price can be found in the table below.
iSpecimen forecast for this year
Forecast target price for 02-25-2022: $ 3.69. Positive dynamics for iSpecimen shares will prevail with possible volatility of 2.660%.
iSpecimen information and performance
An downtrend is forecast for this month with an optimal target price of $ 3.626. Pessimistic: $3.42. Optimistic: $4.04
